Metabolic Derangement in Acute and Chronic Liver Disorders
- PMID: 28989876
- PMCID: PMC5628538
- DOI: 10.4103/ijem.IJEM_146_17
Metabolic Derangement in Acute and Chronic Liver Disorders
Abstract
Aims: This study aims to assess glycemic and lipid derangement in acute and chronic liver disorders.
Materials and methods: A cross-sectional study was conducted on 104 patients diagnosed with acute or chronic liver disorder. Acute liver disease (ALD) patients were 40 and chronic liver disease (CLD) patients were 64.
Results: The mean value of fasting plasma glucose (FPG) in patients with ALD was 91.8 ± 5.4 mg/dl and in CLD was 115.7 ± 17.9 mg/dl, the difference was significant. The mean value of A1c was 4.3 ± 0.6 in ALD and 6.1 ± 0.8 in CLD, the difference was significant. In patients with CLD mean cholesterol was higher 177.4 ± 28.8 mg/dl when compared to ALD 140 ± 35.1 mg/dl, but the difference was not significant. ALD patients' high-density lipoprotein (HDL) was 50.4 ± 5.1 mg/dl, and in CLD patients, HDL was 44.4 ± 6.1 mg/dl. In CLD mean triglyceride (T) was 148.9 ± 6.4 mg/dl while in ALD T was 134.8 ± 14.2 mg/dl, the difference was significant.
Conclusions: CLD is associated with glycemic derangement demonstrated by deranged FPG and A1c. In patients of ALD, no metabolic derangement was observed.
Keywords: A1c; acute liver disease; chronic liver disease; metabolic derangement.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).Ann Hepatol. 2023 Jul-Aug;28(4):101108. doi: 10.1016/j.aohep.2023.101108. Epub 2023 Apr 23. Ann Hepatol. 2023. PMID: 37088421
-
Role of High-Density Lipoprotein Cholesterol (HDL-C) as a Clinical Predictor of Decompensation in Patients with Chronic Liver Disease (CLD).Int J Hepatol. 2021 Dec 24;2021:1795851. doi: 10.1155/2021/1795851. eCollection 2021. Int J Hepatol. 2021. PMID: 34976412 Free PMC article.
-
Correlation of Fasting Lipid Profile in Patients With Chronic Liver Disease: A Descriptive Cross-Sectional Study in Tertiary Care Hospital.Cureus. 2020 Oct 18;12(10):e11019. doi: 10.7759/cureus.11019. Cureus. 2020. PMID: 33214947 Free PMC article.
-
Lipoprotein metabolism in liver diseases.Curr Opin Lipidol. 2019 Feb;30(1):30-36. doi: 10.1097/MOL.0000000000000569. Curr Opin Lipidol. 2019. PMID: 30550414 Review.
-
Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.Ann Med. 2022 Dec;54(1):1548-1560. doi: 10.1080/07853890.2022.2069854. Ann Med. 2022. PMID: 35635048 Free PMC article. Review.
Cited by
-
Upregulation of CCL5/RANTES Gene Expression in the Diaphragm of Mice with Cholestatic Liver Disease.Adv Exp Med Biol. 2023;1408:201-218. doi: 10.1007/978-3-031-26163-3_11. Adv Exp Med Biol. 2023. PMID: 37093429
References
-
- Anstee Q, Jones D. Liver and biliary tract disease. Davidsons Principles and Practice of Medicine. 22nd ed. Elsevier publication; 2014. pp. 932–3. 959-60.
-
- Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120:829–34. - PubMed
-
- Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–81. - PubMed
-
- Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12. - PubMed
-
- Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care. 2004;27:1171–5. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources